Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men

Journal of Steroid Biochemistry and Molecular Biology

Volumn 99, Issue 4-5, 2006, Pages 209-214

  Wilborn, Teresa W ^a   Lang, Nicholas P ^b   Smith, Michelle ^c   Meleth, Sreelatha ^d   Falany, Charles N ^c  

^a SAMFORD UNIVERSITY   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Dehydroepiandrosterone; Pharmacogenetics; Sulfation; Sulfotransferase; Testosterone

Indexed keywords

ANDROGEN; CYTOSOLIC SULFOTRANSFERASE 2A1; PRASTERONE SULFATE; SULFOTRANSFERASE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALLELE; ANDROGEN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SULFATION; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SYNTHESIS;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANDROGENS; BASE SEQUENCE; CYTOSOL; DNA PRIMERS; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SULFOTRANSFERASES; VARIATION (GENETICS);

EID: 33646781304     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.01.006     Document Type: Article

References (23)

1. Falany C.N. Enzymology of human cytosolic sulfotransferases. FASEB J. 11 4 (1997) 206-216
2. Yamazoe K., and Nagata Y. Pharmacogenetics of sulfotransferase. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 159-176
3. Falany C.N., Vazquez M.E., and Kalb J.M. Purification and characterization of human liver dehydroepiandrosterone sulphotransferase. Biochem. J. 260 3 (1989) 641-646
4. Parker Jr. C.R., Falany C.N., Stockard C.R., Stankovic A.K., and Grizzle W.E. Immunohistochemical localization of dehydroepiandrosterone sulfotransferase in human fetal tissues. J. Clin. Endocrinol. Metab. 78 1 (1994) 234-236
5. Her C., Szumlanski C., Aksoy I.A., and Weinshilboum R.M. Human jejunal estrogen sulfotransferase and dehydroepiandrosterone sulfotransferase: immunochemical characterization of individual variation. Drug Metab. Dispos. 24 12 (1996) 1328-1335
6. Parker Jr. C.R., Leveno K., Carr B.R., Hauth J., and Macdonald P.C. Umbilical cord plasma levels of dehydroepiandrosterone sulfate during human gestation. J. Clin. Endocrinol. Metab. 54 6 (1982) 1216-1220
7. Forest M., De Peretti E., and Bertrand J. Developmental patterns of the plasma level of testosterone, androstenedione, 17-hydroxyprogesterone, dehydroepiandrosterone and its sulfate in normal infants and prepubertal children. In: James V.H.T., et al. (Ed). The Endocrine Function of the Human Adrenal Cortex (1978), Academic Press, New York 561-582
8. Labrie F., Belanger A., Cusan L., and Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J. Clin. Endocrinol. Metab. 82 8 (1997) 2403-2409
9. Labrie F. Intracrinology. Mol. Cell. Endocrinol. 78 3 (1991) C113-C118
10. Bosland M.C. The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monogr. 27 (2000) 39-66
11. Andriole G., Bruchovsky N., Chung L.W., Matsumoto A.M., Rittmaster R., Roehrborn C., Russell D., and Tindall D. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 172 4 Pt. 1 (2004) 1399-1403
12. Thomae B.A., Eckloff B.W., Freimuth R.R., Wieben E.D., and Weinshilboum R.M. Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogenomics J. 2 1 (2002) 48-56
13. Society A.C. Cancer Facts Fig. (2001)
14. Nowell S., Ratnasinghe D.L., Ambrosone C.B., Williams S., Teague-Ross T., Trimble L., Runnels G., Carrol A., Green B., Stone A., Johnson D., Greene G., Kadlubar F.F., and Lang N.P. Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev. 13 2 (2004) 270-276
15. Freedland S.J., Aronson W.J., Kane C.J., Presti Jr. J.C., Amling C.L., Elashoff D., and Terris M.K. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J. Clin. Oncol. 22 3 (2004) 446-453
16. Falany C.N., Comer K.A., Dooley T.P., and Glatt H. Human dehydroepiandrosterone sulfotransferase. Purification, molecular cloning, and characterization. Ann. N. Y. Acad. Sci. 774 (1995) 59-72
17. Labrie F., Luu-The V., Labrie C., and Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front. Neuroendocrinol. 22 3 (2001) 185-212
18. Longcope C. Metabolism of dehydroepiandrosterone. Ann. N. Y. Acad. Sci. 774 (1995) 143-148
19. Falany C.A., and Meloche C.N. Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J. Steroid Biochem. Mol. Biol. 77 4-5 (2001) 261-269
20. Meloche C.A., Sharma V., Swedmark S., Andersson P., and Falany C.N. Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab. Dispos. 30 5 (2002) 582-585
21. Shibutani S., Shaw P.M., Suzuki N., Dasaradhi L., Duffel M.W., and Terashima I. Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 19 11 (1998) 2007-2011
22. Duffel T.I., and Apak M.W. Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. Drug. Metab. Dispos. 32 12 (2004) 1501-1508
23. Falany J.L., Macrina N., and Falany C.N. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. J. Steroid Biochem. Mol. Biol. 88 4-5 (2004) 383-391